Evexia Lifecare Limited to launch new products by November 2021

Apart from ISOMETA API product, Evexia Lifecare Limited is also planning to manufacture intermediate mainly use as anti-diabetic and heart diseases at Vadodara based plant location. The Research & Development (R & D) team is at final stage of the 5 more products which the company may launch by November 2021.

The company is at advance stage of acquiring Akola (Maharashtra) based existing plant of one of the manufacturer of ISOMETA API which will increase the production capacity as well as profitability.

The vision of the company to enter into formulation by January 2022, which will give push to the growth of the company for long term. The R & D team has already started work for the formulation plant looking into the opportunity and available market in India as well as across the globe.

The company has started its new branch at Hyderabad location for the trading of pharmaceutical chemicals and the same will likely to contribute Rs. 25-30 Cr turnover per year.

For the above all expansion activities, the company will manage the funds internally only and the board is not expecting any external borrowings.

Shares of EVEXIA LIFECARE LIMITED was last trading in BSE at Rs. 15.3 as compared to the previous close of Rs. 15.4. The total number of shares traded during the day was 793458 in over 1742 trades.

The stock hit an intraday high of Rs. 15.75 and intraday low of 15.2. The net turnover during the day was Rs. 12227686.

Source : Equity Bulls

Keywords